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Abstract
Background
Permanent pacemaker implantation (PPI) following TAVR is a frequent post interventional
complication and its management remains controversial.
Objective
We sought to elucidate the electrophysiological, procedural, and clinical baseline parame-
ters that are associated with and perhaps predict the need for PPI after TAVR in a heteroge-
neous-valve-type real-world cohort.
Methods
Overall, 494 patients receiving TAVR at our center from April 2009 to August 2015 were
screened. ECG analyses and clinical parameters were collected prospectively.
Results
Overall, 401 patients in this all-comers real-world TAVR cohort with a PPI rate of 16% were
included. The mean age was 82 years, and the mean duration to PPI was 5.5 days. A large
proportion of Edwards SAPIEN valves (81%), DirectFlow, CoreValve, and Portico were
implanted. The main indications for PPI were atrioventricular (AV) block III, AV-block Mobitz
type II, bradycardic atrial fibrillation and persistent sinus bradycardia. Between groups with
and without PPI, significant differences were noted in the prevalence of post TAVR balloon
dilatation, resting heart rate, QRS interval, PR interval with a cut-off of >178 ms, left anterior
fascicular block and RBBB in univariate analyses. In the subsequent multiple regression
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analysis, post TAVR balloon dilatation and a PR interval with a cut-off of >178 ms were sig-
nificant predictors of PPI.
Conclusion
This real-world cohort differs from others in its size and heterogeneous valve selection, and
indicates for the first time that patients with post balloon dilatation or prolonged PR interval
are at a higher risk for pacemaker dependency after TAVR.
1 Introduction
Aortic valve stenosis is the most common valvular heart disease in industrialized nations[1].
Transcatheter aortic valve replacement (TAVR) has become a therapeutic option for patients
with severe symptomatic aortic stenosis at high surgical risk[2]. In Germany alone, nearly
16,000 patients were treated with TAVR[3] between 2013 and 2015, and implantation rates are
increasing worldwide. Excellent results obtained in clinical trials have initiated a reassessment
of the recommendations for the treatment of aortic stenosis and hence may trigger a wider use
of TAVR.
High degree AV-block requiring permanent pacemaker implantation (PPI) and paravalvu-
lar leakage account for the most common complications following TAVR. The PPI rates have
varied from 2–51% in the current literature[4][5][6]. New valve designs have been developed
and are now commonly used in order to minimize the risk of paravalvular leakage, which con-
stitutes an important predictor of poor outcomes after TAVR[7][8]. Early results of the third-
generation devices showed an increase in conduction disturbances (e.g., Edwards SAPIEN 3
(ES3), (Edwards Lifesciences, Inc., Irvine, CA, USA) requiring PPI[9], probably due to its spe-
cial design (e.g., the outer sealing skirt of the ES3) and presumed increased surface pressure
and consecutive higher compression of the peripheral tissue[10]. As a limitation, patients with
pre-implanted pacemakers were not excluded from the baseline cohorts, particularly those
patients who were in the PARTNER trials[11][12]. A total of 22.9% (n = 35/153) of the patients
in the PARTNER B trial and 11.7% (n = 118/1011) in the PARTNER 2 trial had pre-implanted
pacemakers and were not excluded from the analysis regarding the new onset (PARTNER: 8/
179 vs. 8/144; PARTNER 2: 85/1011 vs. 85/893) of pacemaker dependency following TAVR.
This inclusion may lead to a relevant underestimation of pacemaker dependency following
TAVR.
Most importantly, the characterization of frequent complications becomes increasingly
important, especially in the case of further widening of the TAVR-indication to include inter-
mediate risk patients. Younger and intermediate risk patients risk might experience more fre-
quent pacemaker replacements due to their longer life expectancy, which would be associated
with an increased risk of complications[13]. Some studies investigating possible predictors of
pacemaker dependency have been published. However, interpreting these data is complex due
to the vast parameter collections, different endpoints and small sample sizes in at least some of
the studies. Other studies have merely investigated the occurrence of conduction disturbances
such as new left bundle branch block (LBBB), whereas others have concentrated on the predic-
tors of pacemaker dependency in one particular valve design[4].
There is confusion about the optimal management of PPI after TAVR, and hence, many
centers started to implant PPI early after TAVR to avoid complications and to ensure postop-
erative mobilization and early discharge of the patients. This practice may be contradicted
by the principles of individualized patient treatment and the “choosing wisely” paradigm.
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Therefore, the present work provides an insight and new evidence from an unselected, large,
single-center, real-world cohort in which careful and individual decision-making was utilized
regarding PPI following TAVR.
In this analysis of prospectively collected data related to TAVR and post interventional PPI,
we also sought to elucidate the electrophysiological, procedural and clinical baseline parame-
ters associated with PPI following TAVR in an all-comers real-world cohort with heteroge-
neous valve selections.
2. Methods
2.1 Patient population and study design
We analyzed the ECGs and clinical parameters of 494 consecutive patients treated with trans-
femoral (tf-) TAVR from April 2009 to August 2015 at our institution. Our study was
approved by the local ethics committee (Ethic committee Go¨ttingen: 22/4/11) and was con-
ducted according to ICH-GCP standards–due to the retrospective character of the study, the
need for consent was waived by our local ethic committee. Patients with in-hospital deaths, a
previously implanted pacemaker, ICD or CRT systems and valve-in-valve procedures were
excluded. Patients with already implanted devices were excluded because no differentiation
between already existing conduction disturbances and those caused by TAVR would be per-
formed. Patients who died in the peri-interventional phase were excluded for similar reasons.
Patients with valve-in-valve procedures were excluded because pressure on the perivalvular tis-
sue through TAVR is different in this situation. The assumed pathomechanism of conduction
disturbances following TAVR differs in valve-in-valve procedures.
2.2 Procedures and decision making
Selection of the TAVR patients was performed by our local Heart Team consisting of interven-
tional cardiologist, cardiac surgeons and anesthesiologists. All patients were implanted by one
of three leading cardiologists together with a cardiac surgeon and treated using a standardized
method according to the local protocol.
Different valve types and generations of valve types were implanted. Careful valve selection
was completed individually for each patient by the Heart Team. Decisions for pacemaker
implantations were performed assessing each indication, and the timing of the implantation
was determined individually according to the current ESC guidelines[14]. Regarding point of
time, there was no automatism or routinely pacemaker implant on same day. We considered
an earlier PPI if patients had persistent conduction disturbances, predominant complete AV
block, poor clinical stability due to e.g. delir, temporary pacemaker dislocation and medica-
tion. Accordingly, we considered later PPI if conduction disturbances were not continuously
detectable, were asymptomatic, in some cases a “watch and wait” strategy was chosen for at
least one day. If patients showed signs of an infection, PPI was postponed as well.
Patients were monitored on our intermediate care unit following TAVR procedure. Temporary
pacemaker was removed at first post procedural morning if there were no signs of serious conduc-
tion disturbances in the continuous ECG monitoring. During the first 24 h following TAVR an
invasive blood pressure monitoring, continuous ECG analyses and oxygen saturation were estab-
lished. After 24 h patients were monitored with a continuous ECG solely until discharge.
2.3 Data collection
ECG examinations were routinely performed at admission and discharge. Clinical parameters
as well as laboratory values were collected prospectively.
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2.4 Statistical analysis
As part of the statistical analysis, the PR interval was dichotomized using a cut-off value of 178
ms. This cut-off value maximized Youden’s J index[15]. For calculating Youden’s J index, a PR
interval higher than the cut-off was considered a predictor for requiring a pacemaker.
To identify variables that affect the probability of requiring a pacemaker after TAVR, a uni-
variate logistic regression for each of the 42 identified risk factors was performed. The p-values
and confidence intervals are reported. The variables with a p-value <5% in the univariate
logistic regression were included in a multiple logistic regression. The missing values were
then imputed using the multivariate imputation by chained equations (MICE) method[16]
(16). For the multiple logistic regression of the pooled results based on 300 imputations, the
odds ratios, 95% confidence intervals, and two-sided p-values are reported. P-values smaller
than 5% are referred to as statistically significant. Due to the explorative nature of these analy-
ses the p-values were not adjusted for multiple testing. The time to pacemaker implantation is
displayed by a Kaplan-Meier curve. All statistical analyses were performed in R version 3.3.3
[17]. Graphics were done with Graph pad prism (LaJolla, CA, USA).
3 Results
3.1 Study population
Over a period of six years, a total of 494 patients were treated with tf-TAVR at our institution.
A total of 93 patients were excluded from the analysis for the following reasons: a previously
implanted pacemaker was present in 63 cases (13%), peri-interventional death occurred in 23
cases (5%) and a valve-in-valve procedure was performed in 7 cases (14%) (Fig 1). Therefore,
401 patients were analyzed with regards to pre- and post-procedural ECG parameters, risk
scores and baseline parameters. Only pre-procedural ECG parameters were used for the analy-
ses of the PR interval.
The cohort included “typical” TAVR patients characterized by high age (mean age 82
years) and high perioperative risk (Log. EuroScore 20.5; EuroScore II 5.8, STS score 5.5)
(Table 1).
A PPI was required in 64 out of 401 patients (15.9%). The main indications were
complete AV-block, AV-block IIb (Mobitz) and symptomatic bradycardia with a mean
duration time to pacemaker implantation of 5.4 ± 4 days (median 5 days). Approximately
two-thirds of the treated population suffered from coronary artery disease (CAD), and nearly
40% had a past medical history of coronary artery bypass graft (CABG) or percutaneous coro-
nary intervention (PCI) prior to the TAVR procedure. A history of atrial fibrillation was pres-
ent in 192 patients (47.9%). Impaired renal function was diagnosed in 211 patients (52.6%)
(Table 1).
3.2 Valve selection and pacemaker rates
The following valve types were implanted: Edwards SAPIEN (Edwards Lifescience, Irvine, CA,
USA) in n = 38 (9.4%), Edwards SAPIEN XT (Edwards Lifescience, Irvine, CA, USA) in
n = 151 (37.6%), Edwards SAPIEN 3 (Edwards Lifescience, Irvine, CA, USA) in n = 134
(33.4%), CoreValve System 1st Generation (Medtronic, Minneapolis, MN, USA) in n = 31
(7.7%), Portico (St. Jude Medical, Saint Paul, MN, USA) in n = 16 (4.0%) and Direct Flow
(Direct Flow Medical, Santa Rosa, CA, USA) in n = 31 (7.7%) (Fig 2).
There was no statistically significant difference regarding PPI rates between valve types
[Edwards SAPIEN 18.4% (7 PPI in 38 TAVR procedures) vs. Edwards SAPIEN XT 10.5% (16/
151) vs. Edwards SAPIEN 3 20.8% (28/134) vs. CoreValve System 1st Generation 19.3% (6/31)
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vs. Portico 25% (4/16) vs. Direct Flow 12.9% (4/31)] or valve sizes in our analysis (Table 2;
Fig 3).
3.3 Comparison of clinical parameters of patients with and without the
need for a pacemaker following TAVR
Eligible patients were divided into two groups: patients with an indication for a pacemaker vs.
patients without an indication for a pacemaker following TAVR.
Multiple clinical parameters (patients’ medical history, laboratory blood tests, peri-inter-
ventional measurements) were analyzed with regards to differences between the patients
requiring pacemaker therapy and those who did not (Table 2). Post dilatation (intraproce-
dural) to attenuate paravalvular leakage was significantly more common in patients requiring
PPI (50% (32/64) vs. 27.8% (94/337); p = 0.002). A history of atrial fibrillation (p = 0.077) and
mild to moderate renal impairment (GFR 30–60 ml/min; p = 0.085) showed a trend but did
not reach statistical significance. Other clinical parameters such as age, different risk score
models (EuroScore I+II, STS score), amount of contrast medium, or the total procedure time
were not of statistical significance (Table 2).
Fig 1. Analyzed cohort of 401 included patients and 93 patients excluded due to different reasons (prior pacemaker or ICD implantation, peri-interventional
death and valve-in-valve procedures).
https://doi.org/10.1371/journal.pone.0204503.g001
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3.4 Comparison of ECG parameters of patients with and without the need
for a pacemaker following TAVR
Lower resting heart rate (as a continuous variable; p = 0.026), QRS duration (as a continuous
variable; p = 0.02), a PR interval cut off value of>178 ms (p = 0.003), left anterior fascicular
block (p = 0.001), a pre-existing RBBB and pathological electric heart axis (marked left and
right axis deviation and right axis deviation; p = 0.034) significantly affect the probability of a
pacemaker implantation.
Table 1. Characteristics of the patients at baseline (yr = years; CABG = coronary artery bypass graft;
COPD = chronic obstructive pulmonary disease; GFR = glomerular filtration rate).
Patient characteristics at baseline
Age—yr 82 ± 5.1
Male sex 139 (34.7)
Log. EuroScore I 20.5 ± 13
Log. EuroScore II 5.8 ± 5
Body-mass index 26.9 ± 5
STS risk score 5.5 ± 3
Coronary artery disease 265 (66.1)
Previous CABG 41 (10.2)
Previous PCI 121 (30.2)
Cerebral ischemic event 56 (14.0)
Peripheral vascular disease 67 (16.7)
Diabetes mellitus 132 (32.9)
COPD 72 (18.0)
Atrial fibrillation 192 (47.9)
paroxysmal 81 (20.2)
persistent 26 (6.5)
permanent 85 (21.2)
Renal failure 211 (52.6)
GFR < 30 40 (10.0)
Mean ± standard deviation or frequency (%)
https://doi.org/10.1371/journal.pone.0204503.t001
Fig 2. Distribution of the different valve types in the entire cohort (n = 401).
https://doi.org/10.1371/journal.pone.0204503.g002
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3.5 Multiple logistic regression analysis
Statistically significant parameters in the univariate analysis as well as the medically justified
interactions between LAFB and QRS, between LBBB and QRS, and between RBBB and QRS
Table 2. Results of univariate analysis of baseline clinical, ECG and procedural parameters.
Clinical baseline parameters Mean Standard deviation p—value
- Age (years) 82.2 5.2 0.724
- EuroScore I 19.2 12.6 0.067
- EuroScore II 5.5 5.1 0.578
- STS score 5.4 3.2 0.512
- BSA 1.8 0.2 0.772
- Valve type NA NA 0.159
- Valve size NA NA 0.318
- LVEF (cut off 50%) NA NA 0.508
- Coronary artery disease NA NA 0.091
- Prior PCI NA NA 0.467
- CABG NA NA 0.696
- Peripheral vascular disease NA NA 0.969
- Cerebral ischemic disease NA NA 0.790
- COPD NA NA 0.762
- Diabetes NA NA 0.433
- Chronic kidney disease NA NA 0.504
- GFR < 30 ml/min NA NA 0.392
- GFR < 60 ml/min NA NA 0.085
- Creatinine (mg/dl) 1.18 0.6 0.328
Laboratory values
- Hemoglobin (mg/dl) 12.3 5.8 0.558
- Sodium (mmol/l) 139.2 3.8 0.206
- Potassium (mmol/l) 4.0 0.5 0.614
- TSH (mU/l) 1.1 1.1 0.521
- Creatine kinase (U/l) 94.7 139.8 0.638
- Difference in Creatine kinase (U/l) 30.0 174.6 0.790
Procedural parameters
- Length of procedure (min) 68.6 34.9 0.217
- Amount of contrast medium (ml) 140.9 58.9 0.444
- Fluoroscopy time (min) 15.1 9.6 0.867
- Post dilatation NA NA 0.002
ECG parameters
- Resting heart rate (bpm) 74.1 14.6 0.026
- QRS time (continuous) 101.9 21.9 0.020
- AV-block I˚ NA NA 0.486
- PR interval (cut-off> 178 ms) NA NA 0.003
- Left anterior fascicular block NA NA 0.001
- Left bundle branch block NA NA 0.194
- Right bundle branch block NA NA 0.001
- Pathological electrical heart axis NA NA 0.034
- Change in electrical heart axis NA NA 0.723
- Atrial fibrillation NA NA 0.077
https://doi.org/10.1371/journal.pone.0204503.t002
Insights into PPI following TAVR in a real-world cohort
PLOS ONE | https://doi.org/10.1371/journal.pone.0204503 October 17, 2018 7 / 14
were tested in a multiple regression model. The interaction between LAFB and RBBB/LBBB
could not be estimated. None of the listed interactions was significant. Therefore, we present
the model without interactions (Table 3)). In this model, post dilatation (OR 2.219; 95% CI
(1.106; 3.667); p = 0.007) and a PR interval above 178 ms (OR 0.412; 95% CI (1.058;5.134);
p = 0.027) remained as independent predictors for PPI therapy following TAVR. Other param-
eters were no longer significant in the multiple regression analysis (resting heart rate p = 0.126;
QRS time p = 0.473; left anterior fascicular block p = 0.063; left and RBBB, p = 0.190 and
p = 0.208, respectively).
3.6 Post procedural time to pacemaker implantation
The mean time to pacemaker implantation following TAVR was 5.5 days. Fig 4 shows the ear-
liest implantation on day 1 post intervention and the latest implantation on day 18 post
TAVR. For comparison, the mean length of the index procedure hospital stay of the most
recent TAVR trial was 5.75 days and is marked with a red line(6).
Fig 3. Different valve types with total implantation number and proportion of pacemaker patients (n = 401).
https://doi.org/10.1371/journal.pone.0204503.g003
Table 3. Multiple logistic regression analysis of predictors of permanent pacemaker dependency (n = 401).
Odds ratios (OR) Lower and upper confidence interval for
OR
p-value
(Intercept) 0.177 0.013; 2.427 0.195
QRS duration (continuous variable) 1.007 0.988; 1.027 0.464
Left anterior fascicular block 4.966 0.779; 31.658 0.090
Left bundle branch block 0.301 0.045; 2.024 0.217
Right bundle branch block 2.174 0.687; 6.885 0.187
Post TAVR dilatation 2.014 1.106; 3.667 0.022
Resting heart rate (continuous
variable)
0.984 0.963; 1.005 0.144
PR interval (cut off 178 ms) 2.331 1.058; 5.134 0.0358
https://doi.org/10.1371/journal.pone.0204503.t003
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4 Discussion
4.1 Pacemaker implantation after TAVR
We sought to elucidate the electrophysiological, procedural, and clinical baseline parameters
that are associated with and perhaps predict the need for permanent pacemaker implantation
after TAVR in a heterogeneous-valve-type real-world cohort. The key feature of our study is
that, unlike other published studies, we examined a large sample size of 401 consecutive
patients with a variety of valve types, and our data therefore more closely represent a typical
real-world cohort.
Our patients are comparable to other published TAVR cohorts [3] characterized by high
age and being a high risk population (82 vs. 81 years; EuroScore I 19.2 vs. 18.3 STS 5.4 vs. 5),
and our cohort represents a typical collective treated in accordance with the current guidelines
[1].
It may be assumed that the risk of PPI following TAVR differs between each valve type;
therefore, specific trials would be ideal to individualize TAVR therapy. Nevertheless, TAVR is
a rapidly disseminating therapy performed in a growing number of hospitals in different coun-
tries with different social and health economic infrastructure. Therefore, regional availability
of valve types may vary, which may support the utility of our study.
A PPI rate of 15.9% is comparable to other published cohorts consisting of various valve
types of different generations and manufacturers[3][4]. The time to PPI implantation (5.5
days) in our study is also comparable to large TAVR cohorts as well as the PARTNER trial and
registry, which had a mean time to implantation of 4.1 days[5]. This result may reflect the care-
ful and individualized decision making undertaken for each patient. Nevertheless, the PPI
rates differ between real-world collectives, such as our cohort, and others, such as selected col-
lectives like the PARTNER trials, in which the PPI rate was markedly lower (8.5% in PART-
NER 2)[12][18][19]. The difference between implantation rates in general is not completely
clear. Future studies should prospectively examine the role of a specific valve in this context.
A meta-analysis by Siontis et al. reported the predictors of PPI following TAVR in 11,210
patients from 41 trials (average of 273 pts. per study) [4]. Of note, our study would have been
Fig 4. Kaplan-Meier analysis of PPI following TAVR in the pacemaker group (n = 401). Mean length of index
procedure hospital stay (5.75 days) in the SURTAVI trial[6] marked with a red line.
https://doi.org/10.1371/journal.pone.0204503.g004
Insights into PPI following TAVR in a real-world cohort
PLOS ONE | https://doi.org/10.1371/journal.pone.0204503 October 17, 2018 9 / 14
the largest single-center cohort in this analysis. They found first-degree AV-block, left anterior
hemiblock, RBBB and male sex to be significant predictors of PPI. Most of the risk factors
identified in this meta-analysis are mainly confirmed by our results from this real-world
cohort. The first-degree AV-block was not significant in our population; however, we did
show that a longer PR interval is associated with an increased risk of PPI, indicating that AV-
block may be a significant factor in a larger sample size. The same might be true in patients
with a pre-existing left anterior hemi block, which reached statistical significance in univariate
analysis. The multivariate analysis resulted in a high odds ratio, but statistical significance was
not reached. The presence of RBBB was also a significant predictor in the univariate analysis of
our cohort.
4.2 Post TAVR balloon dilatation
Post TAVR balloon dilatation is required if the valve was not expanded sufficiently and/or a
relevant regurgitation was still detectable. In this case, the operator further expands the TAVR
device with a balloon to minimize aortic regurgitation. Pre- and post-balloon dilatation were
tested as predictors for the need for PPI following TAVR and pre-balloon dilatation analyses
remain contradicting. Post- balloon dilatation failed to show significant impact on pacing fol-
lowing TAVR in an isolated Lotus valve cohort with 228 patients, and a remarkable PPI rate of
32% with a median time to PPI of 3.0 days. [20][21][22]. It was presumed that pre-dilatation
may avoid the need for post-dilatation(17). However, since there was a change in our local pro-
tocol regarding the performing of pre-dilatations, we could not prove this assumption with
our data. In our analysis, balloon dilatation after TAVR proved to be a significant predictor of
PPI. However, significant paravalvular regurgitation (PVR) is a well-accepted risk factor for a
poor outcome following TAVR[7], and interventionalists may rather accept an increased risk
for PPI post TAVR. Nevertheless, our result indicates and strengthens the already described
association between mechanical effects of TAVR with consecutive tissue trauma and conduc-
tion disturbances[21]. However, on the basis of different published research in this controver-
sial field, it is not clear if there exists a difference in prognosis between the grades of PVR.
Some authors even suggested that mild PVR could be accepted in selected patients[7][23][24].
Therefore, depending on future data, post TAVR balloon dilatation may be carefully evaluated
in patients with only mild PVR due to the higher risk of PPI in these patients.
4.3 ECG parameters
The aortic annulus is located near the AV node and the cardiac conduction system, and the
supraventricular structures may be especially influenced by the implantation pressure. In light
of this fact, there is evidence that pre-existing conduction abnormalities such as AV-block I,
RBBB or LBBB as well as left anterior fascicular branch block may predict conduction distur-
bances following TAVR[10]. We also detected a significant effect of a PR interval of above 178
ms on the need for PPI following TAVR. We are not aware of any literature describing a cut-
off value in PR interval, although a PR interval with a cut-off value of 200 ms (first degree AV-
block) was found to be a predictor of PPI[18]. In our statistical analysis, the PR interval was
dichotomized using a threshold of 178 ms. This threshold maximized the Youden index, in
other words, it maximized the sum of sensitivity and specificity as a predictor of post-TAVR
PM implantation. Other statistical methods for determining the optimal threshold could have
been considered, for instance the Euclidean distance, the product of sensitivity and specificity,
the accuracy, or the diagnostic odds ratio[25]. Siontis et al. reported in their meta-analysis of
11,210 TAVR patients with a heterogeneous valve selection that first degree AV-block was a
significant predictor of PPI after TAVR[4]. Other studies analyzed only the Edwards SAPIEN
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or the CoreValve and did not find first degree AV-block to be a significant predictor of PPI,
but they did not analyze the PR interval as a continuous variable[5][21]. Accordingly, first-
degree AV-block was not significant in our analysis either, although it may be assumed that a
prolonged PR interval is associated with PPI therapy following TAVR.
Other ECG parameters such as RBBB or left anterior fascicular branch block proved to be
significant in other analyses[4][5]. Although these factors were statistically significant in the
univariate analysis, the results failed to remain significant when inserted in the multiple regres-
sion model. This finding may be mainly driven by the strong influence of the post TAVR bal-
loon dilatation in our analysis. Post balloon dilatation and its potential influence on ECG
parameters were not demonstrated in the other analyses mentioned. These discrepancies may
also be explained by differences in sample size with our sample being substantially larger than
previous investigations.
4.4 Other parameters
No laboratory parameters known to have a potential impact on the cardiac conduction system,
e.g., potassium, hemoglobin or thyroid stimulating hormone, showed any correlation with
PPI, which indicates a pure mechanical pathomechanism as the cause of conduction distur-
bances following TAVR.
Furthermore, we did not detect any association between any of the present comorbidities
or age with the typical surgical risk scores (EuroScore, STS-Score) and PPI following TAVR.
This fact also supports the theory of a pure mechanical pathomechanism and a limited regional
problem of the peripheral structures of the aortic valve.
4.5 Widening of TAVR indication
TAVR is performed around the world with similar results in terms of safety and efficacy. Thus,
there has been a recent increase is interest in expanding the TAVR indication to include inter-
mediate and low risk patients[12]. In this context, PPI as a typical complication gains particu-
lar importance. Younger and low-risk patients are typical surgical candidates, and the
guidelines recommend surgical aortic valve replacement in these patients. Pacemaker rates in
surgical candidates are lower than in published TAVR cohorts (4% GARY surgery vs. GARY
interventional 17.5%)[3][26] In younger patients in particular, a likely change of pacemaker
during the lifetime must be considered, and these younger patients have to be educated regard-
ing this additional risk during the decision making process[13][27][28][29]. In this context, it
is of particular importance to investigate this issue, and it is especially important to determine
the predictors of PPI after TAVR.
4.6 Impact on daily practice
Our results reflect one of the largest single-center cohorts and combine baseline, ECG, and
procedural parameters with regard to their influence on PPI post TAVR. Patients with a base-
line PR interval of> 178 ms might be informed (prior to the TAVR procedure) about their
higher risk of developing serious conduction disturbances, possibly leading to a PPI after
TAVR. Patients who need intraprocedural post dilatation are at increased risk for developing
serious conduction disturbances in the post procedural period. These particular patients may
need to be evaluated more carefully because PPI is more likely. Furthermore, patients with the
above described baseline, ECG, and procedural characteristics who do not develop conduction
disturbances in the very early post interventional phase should be observed in-hospital for up
to 7 days post implantation according to the current guidelines due to their high risk for devel-
oping conduction disturbances[14]. As shown in Fig 4, there are patients with late and very
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late development of conduction disturbances. This work does not provide any solution for this
problem but does show that hospital discharge 5 days after the procedure may be too early to
detect conduction disturbances in some patients. Furthermore, identifying patients who are at
a high risk of PPI appears to be helpful in avoiding prolonged hospitalization.
4.7 Limitations
The present paper contains data of a single center with prospectively collected data. Therefore,
our conclusion is not more than hypothesis generating. Representing a real-world cohort of a
high performing single center in Europe the valve selection was not balanced and reflects a
kind of learning curve in using different manufacturers of transfemoral aortic valves.
5 Conclusion
We investigated predictors of PPI in a large single-center cohort with a heterogeneous valve
selection. Post balloon dilatation of the TAVR prosthesis as a novel predictor and a prolonged
PR interval were associated with a significant higher risk of PPI. This should be taken into
account when post dilatation is considered.
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